Abstract
To properly assess the role of any drug for a specific disease, it would be prudent to examine the benefit to risk ratio of each drug. In this chapter these factors will be examined for not only high-dose methotrexate with leucovorin rescue, but also for the other currently useful drugs in the treatment of osteogenic sarcoma, namely, high-dose ifosfamide with mesna and cisplatinum combined with doxorubicin. Comments will be made about other proposed treatments that, at the current time, have no proven place in the treatment of patients with newly diagnosed primary osteosarcoma.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Jaffe N, Frei E, Traggis D, Watta H. Weekly high dose methotrexate-citrovorum factor in osteogenic sarcoma. Cancer 39:45, 1977.
Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2177, 1979.
Kalifa C, Mlika N, Dubousset J, et al. Experience with the T10 protocol in the pediatric service at the Gustave-Roussy Institute. Bull Cancer (Paris) 75:207–211, 1988.
Rosen G, Nirenberg G. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep 4:11–17, 1982.
Samuels LL, Feinberg A, Moccio DM, et al. Detection by high-performance liquid chromatography of methotrexate and its metabolites in tumor tissue from osteosarcoma patients treated with high dose methotrexate/leucovorin rescue. Biochem Pharmacol 33:2711–2714, 1984.
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based upon the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230, 1982.
Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high dose methotrexate. J Clin Oncol 1845–1850, 1986.
Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma. A ten-year experience. Orthopedics 8:659–664, 1985.
Ramanna L, Waxman A, Binney G, et al. Thallium-201 scintigraphy in bone sarcoma: comparison with gallium-67 and technetium-MDP in the evaluation of chemotherapeutic response. J Nucl Med 31:to, 1990.
Rosen G, Loren G, Ramanna L, et al. Osteogenic sarcoma: early evaluation of preoperative chemotherapy with thallium-201 scintigraphy. In: Proc Am Soc Clin Oncol, abstract 97, May, 1991.
Chawla SP, Rosen G, Lowenbraun S, et al. Role of high dose ifosfamide in recurrent osteosarcoma. In: Proc Am Soc Clin Oncol 9:A1201, 1990.
Rosen G, Nirenberg A, Caparros B, et al. Cisplatinum in metastatic osteogenic sarcoma. Cisplatinum—Current Status and New Developments. In: Prestayko AW, Crooke ST, Carter SK, Eds. Academic Press, New York, 1980, pp 465–475.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rosen, G. (1993). An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. In: Humphrey, G.B., Koops, H.S., Molenaar, W.M., Postma, A. (eds) Osteosarcoma in Adolescents and Young Adults: New Developments and Controversies. Cancer Treatment and Research, vol 62. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3518-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3518-8_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6561-7
Online ISBN: 978-1-4615-3518-8
eBook Packages: Springer Book Archive